These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38717120)

  • 1. Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
    Bodie S; Curran AK; Gonzalez-Nelson AC; Perry JM; Manning DC; Wasilewski MM
    Headache; 2024 Jun; 64(6):643-651. PubMed ID: 38717120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
    Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
    Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD
    Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J
    Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics.
    Shrewsbury SB; Kori SH; Miller SD; Pedinoff A; Weinstein S
    Curr Med Res Opin; 2008 Jul; 24(7):1977-85. PubMed ID: 18534051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine.
    Noveck RJ; Douglas PS; Chow SC; Mangum B; Kori S; Kellerman DJ
    Drug Des Devel Ther; 2013; 7():619-25. PubMed ID: 23926420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
    Lipton RB; Albrecht D; Bermudez M; Hu J; Hussey E; Levy J
    Headache; 2024 Mar; 64(3):266-275. PubMed ID: 38413540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.
    Shrewsbury SB; Cook RO; Taylor G; Edwards C; Ramadan NM
    Headache; 2008 Mar; 48(3):355-67. PubMed ID: 18179563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies.
    Kellerman DJ; Forst A; Combs DL; Borland S; Kori S
    J Aerosol Med Pulm Drug Deliv; 2013 Oct; 26(5):297-306. PubMed ID: 23273242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
    Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
    Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
    Kori S; Kellerman DJ; Voloshko P; Haugen G
    Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus(®) in Healthy Adults.
    Vutikullird AB; Gillespie M; Song S; Steinfeld J
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):207-14. PubMed ID: 26624976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.
    Kellerman D; Kori S; Forst A; Chang J; Febbraro S; Wutann L; Thomas T; Taylor G; Dodick D
    Cephalalgia; 2012 Jan; 32(2):150-8. PubMed ID: 22174351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
    Dafer RM; Tietjen GE; Rothrock JF; Vann RE; Shrewsbury SB; Aurora SK
    Headache; 2024 Sep; 64(8):983-994. PubMed ID: 38800847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism.
    Cook RO; Shrewsbury SB; Ramadan NM
    Headache; 2009; 49(10):1423-34. PubMed ID: 19751370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
    Mariotti F; Govoni M; Lucci G; Santoro D; Nandeuil MA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3399-3410. PubMed ID: 30425469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.
    Wilson R; Jarvis E; Montembault M; Hamblin JN; Hessel EM; Cahn A
    Clin Ther; 2018 Aug; 40(8):1410-1417. PubMed ID: 30055824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.